Report: Drug companies profit from dual eligibles

Share this article:

The pharmaceutical industry is experiencing a "windfall" from Medicare's coverage of dual eligibles in the Part D drug program, according to a news report.

Companies are benefiting from the transfer of drug coverage for dual eligible beneficiaries from state Medicaid programs to the Medicare prescription drug benefit. The new benefit exempts Part D drugs from "best price" price rebates. Before the implementation of the drug benefit, drug makers were required to give these rebates to state Medicaid programs.

Without the rebates, the annual cost to states for drugs for beneficiaries who are eligible for both Medicare and Medicaid would have been about 25% higher, said Stephen Schondelmeyer, a professor of pharmaceutical economics at the University of Minnesota.
Share this article:

More in News

Long-term care leaders need self-awareness, partnerships to avoid the 'Founder's Trap,' CEO panel advises

Long-term care leaders need self-awareness, partnerships to avoid ...

Strong leaders must be vigilant or they could stifle a company's innovation and growth, a CEO panel said Monday at the 2014 LINK LTC and Senior Living Conference in Chicago.

Coaching sessions reduce hospital readmissions, study finds

An hour-long educational coaching session and up to three follow-up phone calls reduced readmissions by 39% among Medicare patients, a new study finds.

County nursing home weighs heroin addict plan

An Ohio county is evaluating whether 20 beds at its nursing home could be dedicated for heroin addicts during their withdrawal, according to local reports.